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OBJECTIVES: Atopic dermatitis (AD) is a chronic disease fre-
quent in childhood. The treatment is based on regular moistur-
izing of the skin, information to the parents on the chronic
course with recurrent ﬂares, topical anti-infectious therapy for
superinfections and colonization of the skin by staphylococcus
aureus, and topical steroids. The immuno-modulatory
macrolides (tacrolimus and pimecrolimus) represent a new alter-
native to topical steroids. To establish the importance of differ-
ent characteristics of treatment we would apply a conjoint
analysis exercise. Conjoint analysis is a technique to elicit pref-
erences toward atopic dermatitis treatment and can help plan-
ning optimal health care and guiding therapeutic decisions. The
aim of this pilot study is to establishing which characteristics
patients and caregivers consider important in atopic dermatitis
treatment to design conjoint analysis scenarious. METHODS: A
focus group identiﬁed eight treatment characteristics: Long term
adverse events, short term local adverse events, time to response,
length of response after treatment, distribution mode, pharma-
ceutical dosage form, route of administration, frequency of
applications. Caregiver (all parents) gave their opinion rating
each characteristic from 0 (not important) to 100 (very impor-
tant), moreover they could suggest other characteristics.
RESULTS: Twenty parents of children with mild or severe atopic
dermatitis were enrolled. The most important characteristic con-
sidered was: “length of response after suspension treatment”
(mean = 90), followed by “long term adverse events” (mean =
85), “short term local adverse events” (mean = 82), “distribu-
tion mode” (mean = 75), “time to response” (mean = 67). None
suggested other characteristics. In order to evaluate willingness
to pay we will add “out of pocket” costs. CONCLUSIONS: This
pilot study allowed us to identify aspects considered important
by parents for their children treatment. These results will help
us to design a Conjoint Analysis aimed at evaluating utilities and
monetary value of these aspects.
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OBJECTIVES: The aim of this study was to evaluate the impact
of atopic dermatitis (AD) on adults’ quality of life in France.
METHODS: Atopic patients coming spontaneously to their der-
matologist had to ﬁll in Quality of life questionnaires. The SF-
12 scale was administrated. It is composed of two dimensions,
a Physical Component Summary (PCS-12) and a Mental Com-
ponent Summary (MCS-12). The Dermatology Life Quality
Index (DLQI), was also administrated. RESULTS: The popula-
tion [n = 266, mean age: 33.4 years old (sd: 12)] was composed
of 34.2% of men versus 65.8% of women. The average history
of AD was 18 years (sd:13.8). Its severity was determined by the
dermatologist using the SCORAD index: 1.6% present a mild
form of atopic dermatitis, 44.1% a moderate form and 54.3%
a severe form. Mean DLQI total score was 8.8 (sd 5.5) with no
signiﬁcant difference between men, 8.6 (sd 5.3), and women, 8.8
(sd 5.6). According to the SCORAD index, mean DLQI scores
were 6.8 (sd 4.4) for group gathering “mild” and “moderate”
and 10.2 (sd 5.6) for “severe” group. Although Physical dimen-
sion (PCS-12) of SF-12 was not impaired (mean score 50.7, sd
7.3), the Mental dimension (MCS-12) was very low (mean score
39.5, sd 10.6). According to the SCORAD, MCS-12 scores were
respectively 42.8 (sd 9.8) and 36.5 (sd 10.1) for “mild or 
moderate” group and “severe” group (p < 0.0001). CONCLU-
SIONS: The quality of life of patients suffering from Atopic Der-
matitis was impaired. DLQI mean score was 8.8. This study
especially highlights the impact of AD on patient’s mental health
(MCS-12 mean score =39.5), demonstrating the importance 
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OBJECTIVES: Atrial ﬁbrillation (AF) remains a major health
problem affecting 2.2 million adults in the U.S. with an estimated
cost burden of $3 billion annually. AF is also a major and pre-
ventable cause of transient ischemic attack (TIA) and stroke. The
purpose of this research was to identify demographic, clinical
and treatment factors associated with cerebrovascular co-
morbidity in AF and related medical costs. METHODS: Con-
tinuously beneﬁt-eligible patients with a “new” diagnosis of AF
(ICD-9-CM 427.3x) identiﬁed from a large administrative claims
database (N = 43 million) were identiﬁed between 1 Jan 2000–31
Dec 2001 with a variable follow-up period of £6 months.
Patients were stratiﬁed into cohorts based on initial treatment:
no-treatment (n = 40,489), warfarin (n = 6846) and other anti-
coagulants (n = 868). Clinical and demographic factors were
assessed using Cox proportional hazards regression. Medical
costs were examined using a generalized linear model with a
gamma distribution and log-link function to approximate the
non-normal distribution related to health care expenditures for
both AF and non-AF costs. RESULTS: Prior stroke was associ-
ated with a 100 fold greater risk of subsequent stroke (HR =
113.39, 95% CI = 103.22, 124.56) compared to no such history
(baseline risk = 4.7% over ~20 months of follow-up). Increased
risks also were observed with advanced age, prior TIA, left ven-
tricular dysfunction, high stroke risk (multiple co-morbidities)
and hypertension. Lower stroke risk was observed with patients
who received antithrombotic medication (HR = 0.68, 95% CI =
0.54, 0.85) as well as those receiving cardioversion or ablation.
Mean (±SE) AF-related and unrelated costs were $10,355
(±$129) and $7,661 (±$126) respectively. CONCLUSIONS:
These data are consistent with the clinical and demographic pre-
dictors of stroke/TIA. Use of antithrombotic medication appears
to confer an independent protective effect on stroke risk.
However, the costs associated with AF remain high; more aggres-
sive AF management is necessary improve clinical outcomes and
reduce medical costs.
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